首页 | 本学科首页   官方微博 | 高级检索  
     

非小细胞肺癌Bcl-2、PCNA表达的临床研究
引用本文:张程,王鸿程,李万成,唐凤鸣,曹乃清,李艳萍. 非小细胞肺癌Bcl-2、PCNA表达的临床研究[J]. 泸州医学院学报, 2002, 25(6): 471-473
作者姓名:张程  王鸿程  李万成  唐凤鸣  曹乃清  李艳萍
作者单位:1. 贵州省人民医院呼吸内科,贵州贵阳,550002
2. 泸州医学院附属医院呼吸内科
摘    要:目的:探讨Bcl-2(B细胞淋巴瘤/白血病-2)和PCNA(增殖细胞抗核抗原)在非小细胞肺癌中发生、发展中的作用以及Bcl-2表达+PCNA过表达与淋巴结转移的关系。方法:应用免疫组化方法检测40例非小细胞肺癌Bcl-2和PCNA的表达,并研究该表达和肿瘤组织学类型、分化程度、TNM分期、既往慢性支气管、肺病病史等病理学特征之间的关系,以及Bcl-2表达+PCNA过表达复合出现与淋巴结转移的相关性。结果:①Bcl-2和PCNA在非小细胞肺癌中的阳性表达率分别为35%(14/40)和755(30/40),其阳性率因TNM分期和组织分化程度的不同而不同;②Bcl-2和PCNA表达与鳞癌TNM分期显著相关(P<0.05);③PCNA表达与组织学类型,既往病史(慢性支气管、肺病病史)相关(P<0.05)。④中分化-高分化肿瘤与低分化肿瘤的Bcl-2与PCNA的阳性表达率差异无显著性。⑤Bcl-2表达+PCNA过表达复合出现,与淋巴结转移无关。结论:评估非小细胞肺癌Bcl-2、PCNA的表达情况有助于判断病人的预后,为进一步研究该类肿瘤的发生和发展,提供必要的理论依据。

关 键 词:临床研究 非小细胞肺癌 Bcl-2 免疫组织化学 增殖细胞核抗原
文章编号:1000-2669(2002)06-0471-03
修稿时间:2002-08-25

THE EXPRESSION OF BCL-2 AND PCNA IN NON-SMALL-CELL LUNG CANCER
Zhang Cheng,et al. THE EXPRESSION OF BCL-2 AND PCNA IN NON-SMALL-CELL LUNG CANCER[J]. Journal of Luzhou Medical College, 2002, 25(6): 471-473
Authors:Zhang Cheng  et al
Affiliation:Zhang Cheng,et al Department of Respiratory Medicine,People's Hospital of Gui Zhou Province
Abstract:Objectives: To study the role of Bcl-2 and proliferating cell nucclear antigen (PCNA) in pathogenesis and progression of non-small cell lung cancer (NSCLC) and the relationship between the combination of Bcl-2 expression+PCNA higher expression and lymph node involvement. Methods: The immunohistocchemical expression of Bcl-2 and PCNA was investigated in 40 non-small cell lung cancer patients, soas to see whether these phenomena were correlated with clinicopathology such as tumor type, differentiation degree, TNM stage, and the inter relation between expression of Bcl-2 and PCNA was also analyzed. Results: Bcl-2 and PCNA were detectable in 14 of 40(35%)NSCLC and 30 of 40(75%) NSCLC respectively. The percentage of their positive cases varied according to TNM stage or differentiation degree. In squamous cell carcinoma, the expression of both Bcl-2 and PCNA was significantly related to TNM stage (P<0.05), and PCNA expression in NSCLC was also associated with tumor type and past medical history (chronic bronchial or pulmonary disease) (P<0.05). In addition, statistical comparisons revealed no significant differences in the frequence of Bcl-2 expression to histological type, no notable relationship present between the combination of Bcl-2 expression + PCNA higher expression and lymph node involvement. Conclusion: Assessement of the exxpression status of Bcl-2 and PCNA by tumors may provide prognostic information on the clinical behavior of NSCLC and thus contribute much to the study of how it takes place and progresses.
Keywords:Non-small cell lung cancer (NSCLC)  Bcl-2  Proliferating cell nuclear antigen(PCNA)  Immunohistochernisty
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号